Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2005-10-11
2005-10-11
Davis, Zinna Northington (Department: 1625)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C546S307000
Reexamination Certificate
active
06953805
ABSTRACT:
The present invention provides novel compounds of Formula I or Formula II, or the pharmaceutically acceptable salts or prodrugs thereof, pharmaceutical compositions comprising an effective amount of a compound of Formula I or Formula II in combination with a suitable carrier, diluent, or excipient, and methods for treating neurological disorders and neurodegenerative diseases, particularly pain and migraine.
REFERENCES:
patent: 5356902 (1994-10-01), Ornstein
patent: 5446051 (1995-08-01), Ornstein
patent: 5670516 (1997-09-01), Arnold et al.
patent: 5767117 (1998-06-01), Moskowitz
patent: 6579886 (2003-05-01), Bleakman et al.
patent: 6566370 (2003-06-01), Bell et al.
patent: 0 590 789 (1994-04-01), None
patent: WO 98/45270 (1998-10-01), None
patent: WO 01/01972 (2001-01-01), None
patent: WO 01/02367 (2001-01-01), None
Neuroparmacoligy, 37, pp. 25-36 (1998), “Kainate GluR5 receptor subtype mediates the nociceptive response to formalin in the rat”.
Neuropharmacology, 37, pp. 1211-1222 (1998), “Decahydroisoquinolines: novel competitive AMPA/kainite antagonists with neuroprotective effects in global cerebral ischaemia”.
Y. Sahara, et al., “Glutamate Receptor Subunits GluR5 and KA-2 Are Coexpressed in Rat Trigeminal Ganglion Neurons,” The Journal of Neuroscience, vol. 17, No. 17, pp. 6611-6620 (1997).
Z. Alam, et al., “Plasma levels of neuroexcitatory amino acids in patients with migraine or tension headache,” Journal of Neurological Sciences, vol. 156, pp. 102-106 (1998).
Procter, et al., “Possible role of Glu54 glutamate receptors in spinal nociceptive processing in the anaesthetized rat,” Journal of Physiology, 504.P, 101P-102P (1997).
Nikam, et al., The search for AMPA/Gly(N) receptor antagonists: Drugs of the Future, vol. 24, No. 10, pp. 1107-1124 (1999).
Proctor, et al., “Actions of kainite and AMPA selective glutamate receptor ligands on nociceptive processing in the spinal cord,” Neuropharmacology, vol. 37, pp. 1287-1297 (1998).
Bleakman, et al., “Kainate receptor pharmacology and physiology,” Cellular and Molecular Life Sciences, 56/7-8 (1999) 558-556.
National Library of Medicine (NLM), Bethesda, MD, US: Mitsilostas, et al., “Non-NMDA glutamate receptors modulate capsaicin induced c-fos expression within trigeminal nucleus caudalis,” Database accession No. 10003939 & British Journal of Pharmacology, vol. 127, No. 3, pp. 623-630 (1999).
Filla Sandra Ann
Hudziak Kevin John
Mathes Brian Michael
Ornstein Paul Leslie
Davis Zinna Northington
Eli Lilly and Company
Wilson Alexander
LandOfFree
Excitatory amino acid receptor antagonists does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Excitatory amino acid receptor antagonists, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Excitatory amino acid receptor antagonists will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3459500